Teva Pharmaceutical Industries (NYSE: TEVA) is expected to report Q2 earnings on Aug. 1. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Teva Pharmaceutical Industries's revenues will wane -1.0% and EPS will wane -6.3%.

The average estimate for revenue is $4.94 billion. On the bottom line, the average EPS estimate is $1.20.

Revenue details
Last quarter, Teva Pharmaceutical Industries reported revenue of $4.90 billion. GAAP reported sales were 3.9% lower than the prior-year quarter's $5.10 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $1.12. GAAP EPS of $0.74 for Q1 were 24% lower than the prior-year quarter's $0.97 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 52.8%, 60 basis points better than the prior-year quarter. Operating margin was 19.5%, 260 basis points worse than the prior-year quarter. Net margin was 12.9%, 390 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $20.14 billion. The average EPS estimate is $5.02.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,417 members out of 2,490 rating the stock outperform, and 73 members rating it underperform. Among 521 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 515 give Teva Pharmaceutical Industries a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Teva Pharmaceutical Industries is outperform, with an average price target of $45.31.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Teva Pharmaceutical Industries. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.